1.      Abukhaled M, Al Muqbil M, Alghamdi MA, Hundallah K, Suleiman J, Ben-Omran T, et al. Aromatic L-amino acid decarboxylase deficiency in countries in the Middle East: a case series and literature review. Eur J Pediatr. 2023;182(6):2535–45.

2.      Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab. 2011;104 Suppl:S2–9.

3.      Blau N, Pearson TS, Kurian MA, Elsea SH. Aromatic L-Amino Acid Decarboxylase Deficiency. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle

4.      Brennenstuhl H, Jung-Klawitter S, Assmann B, Opladen T. Inherited Disorders of Neurotransmitters: Classification and Practical Approaches for Diagnosis and Treatment. Neuropediatrics. 2019;50(1):2–14.Ng J, Papandreou A, Heales SJ, Kurian MA. Monoamine neurotransmitter disorders--clinical advances and future perspectives. Nat Rev Neurol. 2015;11(10):567–84.

5.      Chenbhanich J, Sringean J, Bhidayasiri R. Beyond the Classic Segawa Disease, GCH1-Associated Neurodegenerative Parkinsonism: Practical Considerations for Physicians. J Mov Disord. 2017;10(2):102–4.

6.      Cherian A, Paramasivan NK, Divya KP. Dopa-responsive dystonia, DRD-plus and DRD look-alike: a pragmatic review. Acta Neurol Belg. 2021;121(3):613–23.

7.      Copyright © 1993-2025, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.

8.      Copyright © 1993-2025, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.

9.      Copyright © 1993-2025, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.

10.  Friedman J, Galosi S. Sepiapterin Reductase Deficiency. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle

11.  Furukawa Y. GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle

12.  Himmelreich N, Blau N, Thöny B. Molecular and metabolic bases of tetrahydrobiopterin (BH(4)) deficiencies. Mol Genet Metab. 2021;133(2):123–36.

13.  Hoffmann GF, Assmann B, Bräutigam C, Dionisi-Vici C, Häussler M, de Klerk JB, et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol. 2003;54 Suppl 6:S56–65.

14.  Ichinose H, Nomura T, Sumi-Ichinose C. Metabolism of tetrahydrobiopterin: its relevance in monoaminergic neurons and neurological disorders. Chem Rec. 2008;8(6):378–85.

15.  Jung-Kc K, Tristán-Noguero A, Altankhuyag A, Piñol Belenguer D, Prestegård KS, Fernandez-Carasa I, et al. Tetrahydrobiopterin (BH(4)) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model. J Inherit Metab Dis. 2024;47(3):494–508.

16.  Kölker S. Metabolism of amino acid neurotransmitters: the synaptic disorder underlying inherited metabolic diseases. J Inherit Metab Dis. 2018;41(6):1055–63.

17.  Kurian MA, Gissen P, Smith M, Heales S, Jr., Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 2011;10(8):721–33.

18.  Lokhande RV, Dherai AJ, Bhagure GR, Udani VP, Kulkarni SD, Ashavaid TF. Cerebrospinal Fluid Biogenic Monoamine Analysis for Diagnosis of Primary Neurotransmitter Disorders. Indian J Pediatr. 2021;88(12):1241–3.

19.  Maines E, Temporin G, Fedrizzi M, Pasqualini A, Junior Masnata L, Campomori A, et al. Formulation and clinical evaluation of carbidopa/levodopa oral solution for the treatment of sepiapterin reductase deficiency. Eur J Pharm Biopharm. 2024;203:114429.

20.  Mohamed FE, Alzyoud L, Ghattas MA, Tabouni M, Fienemann A, Trinh J, et al. Clinical Features of Families with a Novel Pathogenic Mutation in Sepiapterin Reductase. Int J Mol Sci. 2025;26(7).

21.  Ng J, Heales SJ, Kurian MA. Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders. Paediatr Drugs. 2014;16(4):275–91.

22.  Nygaard G, Szigetvari PD, Grindheim AK, Ruoff P, Martinez A, Haavik J, et al. Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency. J Pers Med. 2021;11(11).

23.  Opladen T, López-Laso E, Cortès-Saladelafont E, Pearson TS, Sivri HS, Yildiz Y, et al. Correction to: Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. Orphanet J Rare Dis. 2020;15(1):202.

24.  Pearl PL, Gibson KM. Clinical aspects of the disorders of GABA metabolism in children. Curr Opin Neurol. 2004;17(2):107–13.

25.  Pearl PL, Hartka TR, Taylor J. Diagnosis and treatment of neurotransmitter disorders. Curr Treat Options Neurol. 2006;8(6):441–50.

26.  Pearl PL, Wallis DD, Gibson KM. Pediatric neurotransmitter diseases. Curr Neurol Neurosci Rep. 2004;4(2):147–52.

27.  Ponzone A, Spada M, Ferraris S, Dianzani I, de Sanctis L. Dihydropteridine reductase deficiency in man: from biology to treatment. Med Res Rev. 2004;24(2):127–50.

28.  Prah A, Pregeljc D, Stare J, Mavri J. Brunner syndrome caused by point mutation explained by multiscale simulation of enzyme reaction. Sci Rep. 2022;12(1):21889.

29.  Rizzi S, Spagnoli C, Frattini D, Pisani F, Fusco C. Clinical Features in Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Systematic Review. Behav Neurol. 2022;2022:2210555.

30.  Roubertie A, Opladen T, Brennenstuhl H, Kuseyri Hübschmann O, Flint L, Willemsen MA, et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency: Requirements for safe application and knowledge-generating follow-up. J Inherit Metab Dis. 2024;47(3):463–75.

31.  Sedel F, Ribeiro MJ, Remy P, Blau N, Saudubray JM, Agid Y. Dihydropteridine reductase deficiency: levodopa's long-term effectiveness without dyskinesia. Neurology. 2006;67(12):2243–5.

32.  Segawa M. Autosomal dominant GTP cyclohydrolase I (AD GCH 1) deficiency (Segawa disease, dystonia 5; DYT 5). Chang Gung Med J. 2009;32(1):1–11.

33.  Song B, Ma Z, Liu W, Lu L, Jian Y, Yu L, et al. Clinical, biochemical and molecular spectrum of mild 6-pyruvoyl-tetrahydropterin synthase deficiency and a case report. Fetal Pediatr Pathol. 2021;40(6):707–16.

34.  Teva Galán MD, Esteban Cantó V, Picó Alfonso N, Jover Cerdá J. [GTP cyclohydrolase 1-deficient dopa-responsive hereditary dystonia]. An Pediatr (Barc). 2011;75(1):55–7.

35.  Ünsel-Bolat G, Turan S, Bolat H. A novel MAOA gene variant: Brunner syndrome, a rare syndrome, is associated with a wide range of psychiatric symptoms. Int J Dev Neurosci. 2024;84(8):972–6.

36.  Wassenberg T, Geurtz BPH, Monnens L, Wevers RA, Willemsen MA, Verbeek MM. Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment. Mol Genet Metab Rep. 2021;27:100762.

37.  Zheng X, Ying C, Xie F, Cen Z, Luo W. Novel SPR mutation in first Chinese patient with sepiapterin reductase deficiency: urinary biomarker validation in oldest treated case. Neurol Sci. 2025;46(8):4011–5.